Skip to content
Screener

Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Operating Expenses

Other segment segments

Gyre
$8.7M-7.8%

Similar metrics at other companies

NAG
NAGEPharmaceuticals segment — Operating Expenses
$468K+27.2%
Siebert Financial logo
SIEBSettlement Expense — Operating Expenses
$1.48M
Array Technologies, Inc. logo
ARRYSTI Operations — Operating Expenses
$0
Ovintiv logo
OVVCanadian Operations — Operating Expenses
$798M+34.6%
Ovintiv logo
OVVUsa Operations — Operating Expenses
$1.08B-3.6%
Employers Holdings logo
EIGInsurance Operations — Operating Expenses
$194.8M+4.3%

Other financials

Income statement

See full
Revenue$29.1M-2.1%
Gross profit$26.9M-5.9%
Operating income-$14.4M-541%
Net income-$11.7M-471%
EPS (diluted)-$0.12-300%

Balance sheet

See full
Cash & equivalents$43.3M+18.6%
Total debt$3.4M+145%
Total equity$107.9M+17.3%
Total assets$199.3M+30.5%

Cash flow

See full
Operating cash flow-$16.7M-124%
CapEx$262.0K-21.8%
Free cash flow-$17.0M-118%

Valuation

See full
Market cap$712.55M+11.2%
Enterprise value$672.68M+11.0%
P/S-0.1×

Profitability

See full
Gross margin94.3%-1.7pp
Operating margin-14%-18.7pp
Net margin-13.4%-15.1pp
FCF margin-5.1%

Returns & leverage

See full
Return on equity-16%-18.3pp
Debt / equity0.0×
Current ratio4.3×-1.1×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 5:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-340448
Line itemGyre PharmaceuticalsGyreTotal
Research and development - related parties4,8364,836
General and administrative4,2683,5947,862
Transaction costs502502
Total segment operating expenses34,7648,69943,463
Loss from segment operations(5,667)(8,691)(14,358)
Other segment (loss) income, net:
Interest income252488740
Other expense, net(391)(552)(943)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses?
Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — operating expenses of $34.76M in Q2 2026.
How has Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses changed year-over-year?
Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses increased by 54.2% year-over-year, from $22.54M to $34.76M.
What is the long-term trend for Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses?
Over 2 years (2023 to 2025), Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses has grown at a 8.1% compound annual growth rate (CAGR), from $84.36M to $98.64M.
What does gyre pharmaceuticals — operating expenses mean?
This is the aggregate of all costs incurred to maintain the segment's daily operations, excluding the cost of goods sold. It provides a comprehensive view of the total burn rate or operational overhead required to sustain the segment's business activities.

Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — operating expenses.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude